Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

278
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
278
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

918
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
918
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

936
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
936
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.1K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.1K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

711
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
711
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

1.4K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A brief history of the CNS cholinergic transmission.

Handbook of clinical neurology·2025
Same author

Resistance and resilience to Alzheimer's disease in Down syndrome.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Early loss of locus coeruleus innervation promotes cognitive and neuropathological changes before amyloid plaque deposition in a transgenic rat model of Alzheimer's disease.

Neuropathology and applied neurobiology·2022
Same author

Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery.

Neuropharmacology·2020
Same author

Sex differences in Alzheimer disease - the gateway to precision medicine.

Nature reviews. Neurology·2018
Same author

Sex and Gender Differences in the Brain Cholinergic System and in the Response to Therapy of Alzheimer Disease with Cholinesterase Inhibitors.

Current Alzheimer research·2018

Related Experiment Video

Updated: Sep 30, 2025

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

43.0K

Reimagining cholinergic therapy for Alzheimer's disease.

Ezio Giacobini1, A Claudio Cuello2,3, Abraham Fisher4

  • 1Department of Internal Medicine, Readaptation and Geriatrics, Faculty of Medicine, University of Geneva Hospitals, University of Geneva, CH 1226 Geneva, Switzerland.

Brain : a Journal of Neurology
|March 15, 2022
PubMed
Summary

Cholinesterase inhibitors are key for Alzheimer's disease (AD) symptom management. New research explores novel cholinergic therapies and nerve growth factor pathways to potentially slow AD progression.

Keywords:
Alzheimer’s diseasecholinesterase inhibitorsmuscarinic agonistsnerve growth factor

More Related Videos

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.0K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.4K

Related Experiment Videos

Last Updated: Sep 30, 2025

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

43.0K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.0K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.4K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gerontology

Background:

  • Cholinergic neurotransmission enhancement via cholinesterase inhibitors is the primary treatment for Alzheimer's disease (AD) cognitive and behavioral symptoms.
  • Four of six approved AD therapies are acetylcholinesterase inhibitors, highlighting the importance of the cholinergic system.
  • Memantine and aducanumab represent other therapeutic strategies targeting different pathologies in AD.

Purpose of the Study:

  • To provide an updated review of the basal forebrain cholinergic system in relation to cognition and AD therapy.
  • To discuss the origin, mechanism, clinical effects, advantages, and limitations of cholinergic therapy for AD.
  • To explore novel therapeutic avenues, including M1 muscarinic receptor agonists and nerve growth factor pathways.

Main Methods:

  • Review of current literature on cholinergic system function and AD.
  • Analysis of clinical studies on cholinesterase inhibitor efficacy and disease-modifying potential.
  • Examination of emerging research on muscarinic receptors and nerve growth factor in AD.

Main Results:

  • Cholinergic therapy remains central to AD symptom management, with evidence suggesting long-term efficacy and potential disease-modifying effects of cholinesterase inhibitors.
  • Novel M1 muscarinic receptor agonists show disease-modifying potential.
  • A newly discovered nerve growth factor pathway is implicated in basal forebrain maintenance and AD deregulation.

Conclusions:

  • Cholinergic therapy is crucial for managing AD symptoms, with cholinesterase inhibitors offering symptomatic relief and potential disease modification.
  • Newer agents like selective M1 agonists and understanding nerve growth factor pathways offer promising avenues for future AD treatments.
  • Optimizing current cholinergic approaches and developing novel strategies are essential to enhance clinical effects and slow disease progression in AD.